RNS Number : 1276L
NetScientific PLC
02 July 2014



NetScientific plc

('NetScientific' or the 'Group')

Research Programme in DNA Sequencing



NetScientific (AIM:NSCI), the biomedical and healthcare technology investment group, is pleased to announce that, to complement and reinforce its personalised medicine platform, Nanopore-II (a new US division of NetScientific) has secured an important research programme in DNA sequencing with a research institute in the United States.


This programme is in a fast-growing, valuable and very competitive field. Notwithstanding the crowded IP landscape, feedback from the US Patent Office on the initial filings is encouraging.



For further information, please contact

NetScientific plc                                                         

Tel: +44 (0) 20 3590 8877

Farad Azima, Chief Executive Officer

Peter Thoms, Chief Financial Officer

Liberum (Nomad & Broker)                                      

Tel: +44 (0) 20 3100 2222

Chris Bowman / Christopher Britton / Thomas Bective

Bell Pottinger                                                            

Tel: +44 (0) 20 7861 3232

Daniel de Belder




Company website: www.netscientific.net




NetScientific is a healthcare and life sciences company with global reach that funds and develops technologies that offer transformative benefits to peoples' lives and society through improved diagnosis, prognosis and treatment. The group is primarily focused on identifying and developing cutting edge technologies with applications in several: (i) cardiovascular; (ii) liver; (iii) cancer; (iv) metabolic; and (v) digital health.


This information is provided by RNS
The company news service from the London Stock Exchange